Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VIP152 (BAY 1251152)
VIP152 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose escalation of VIP152 (BAY 1251152) / PART 1 (Completed) | EXPERIMENTAL | Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL |
| Dose expansion of VIP152 (BAY 1251152) / PART 2 | EXPERIMENTAL | Investigating VIP152 (BAY 1251152) in a dose expansion cohort in patients with solid tumors and aggressive NHL |
| Dose escalation of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 3 | EXPERIMENTAL | Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose escalation cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI. |
| Dose expansion of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 4 | EXPERIMENTAL | Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose expansion cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI. |
| Name | Type | Description |
|---|---|---|
| VIP152 (BAY 1251152) | DRUG | The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles. |
| VIP152 (BAY 1251152) 30 mg | DRUG | 30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle. |
| Keytruda | DRUG | 200 mg IV fixed dose once every 3 weeks of a 21 day cycle |
| VIP152 (BAY 1251152) 15 mg | DRUG | The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles. |
Part 2 (Global), Part 3 (US Only), and Part 4 (US Only) Inclusion Criteria: * Male or female patients aged \>/=18 years * Patients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapies with MYC expression or k...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
VIP152 is an investigational small molecule being studied in oncology for the treatment of neoplasms, specifically advanced cancer. It is being developed by Vincerx Pharma, Inc. as a potential therapy for patients with advanced solid tumors and other cancers, and it has been evaluated in a Phase 1 dose escalation study.
VIP152 targets P-TEFb/CDK9, a protein complex involved in regulating transcription. By inhibiting CDK9 within the P-TEFb complex, VIP152 is designed to disrupt transcription of genes that cancer cells rely on for growth and survival, which is the mechanistic rationale for its study in advanced cancers.
VIP152 is being developed by Vincerx Pharma, Inc., a biopharmaceutical company whose common stock trades under the ticker symbol VINC. Vincerx Pharma is the sponsor of the clinical program evaluating VIP152 in patients with advanced cancer.
VIP152 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 program consisted of a dose escalation study in patients with advanced cancer, and the drug remains in early-stage clinical evaluation.
VIP152 has been studied in the Phase 1 trial NCT02635672, titled "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer." The trial enrolled 110 patients with neoplasms across the United States, Chile, and Spain, and it is now completed.
Yes, VIP152 is also known as BAY 1251152. The compound was originally developed by Bayer as BAY 1251152 and later became known as VIP152 under development by Vincerx Pharma, Inc. Both names refer to the same small molecule CDK9 inhibitor being studied in advanced cancer.